HCP To Buy Life Science Asset, Boost West Cambridge Cluster
Zacks Investment Research | Sep 10, 2019 06:49AM ET
Strengthening its West Cambridge footprint, HCP, Inc. (NYSE:HCP) recently executed a binding agreement to acquire a 224,000-square-foot, LEED Gold laboratory building located at 35 CambridgePark Drive for $332.5 million.
The transaction, expected to close around December 2019, will expand HCP’s footprint in the Boston life science market, consisting of three core campuses spanning more than 1.3 million square feet of space.
Specifically, 35 CambridgePark Drive is situated in the Cambridge submarket of Boston, MA, and will be acquired from The Davis Companies and Invesco Real Estate (Invesco). The property is 100% leased to five life science tenants consisting of both emerging biopharmaceutical companies and established large-cap ones. Additionally, the property’s weighted average lease term stands at more than 10 years and it carries weighted average lease escalators of 3%. Understandably, long-lease terms and high-quality tenants will assure steady growth in cash flows for HCP.
Additionally, the Class A life-science building offers more than 10,000 square feet of common amenity space, consisting of a lobby, a fitness center, a full-service restaurant and abundant green space and outdoor seating. Further, with its proximity to the busy MBTA Alewife Red Line station and bus terminal, the transit-oriented property offers easy commuter access.
Notably, increasing life expectancy of the U.S. population, and biopharma drug development growth opportunities have promoted the institutional life science and medical-market fundamentals. Hence, life science real estate has grabbed a decent share of attention, and management believes that this real estate category will continue to experience unmatched demand. Additionally, management noted that the cluster strategy adopted by HCP, along with the mix of stabilized and development properties in the portfolio will drive growth for the company’s tenants.
Hence, leveraging on the favorable fundamentals, HCP aims to assemble cluster of assets in three premier life-science epicenters — San Diego San Francisco and Boston — through acquisitions, developments and redevelopments.
In fact, the buyout of 35 CambridgePark Drive reiterates HCP’s targeted focus to increase density in West Cambridge, where it has created up to 440,000 square feet of adjoining space across a modern campus. Specifically, in the first quarter, HCP acquired 64,000-square-foot 87 CambridgePark Drive and a development site at 101 CambridgePark Drive.
These efforts are likely to enable HCP to capture scale and satisfy demand of the company’s growing tenants. However, sale of healthcare properties is likely to result in near-term earnings dilution.
Shares of this Zacks Rank #3 (Hold) company have gained 13.8% over the past six months compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.